TMEM106B drives lung cancer metastasis by inducing TFEB-dependent lysosome synthesis and secretion of cathepsins

[1]  G. Mills,et al.  In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer , 2018, Nature Communications.

[2]  Yiling Lu,et al.  Multiplatform-based Molecular Subtypes of Non-Small Cell Lung Cancer , 2016, Oncogene.

[3]  Alexandra M. Nicholson,et al.  What we know about TMEM106B in neurodegeneration , 2016, Acta Neuropathologica.

[4]  A. Ballabio,et al.  TFEB at a glance , 2016, Journal of Cell Science.

[5]  M. Sardiello,et al.  Transcription factor EB: from master coordinator of lysosomal pathways to candidate therapeutic target in degenerative storage diseases , 2016, Annals of the New York Academy of Sciences.

[6]  M. Jäättelä,et al.  Lysosomes in cancer-living on the edge (of the cell). , 2016, Current opinion in cell biology.

[7]  Jennifer B Dennison,et al.  Functional annotation of rare gene aberration drivers of pancreatic cancer , 2016, Nature Communications.

[8]  Jing Wang,et al.  The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers , 2015, Oncogene.

[9]  Ken Chen,et al.  Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations. , 2015, Cancer research.

[10]  J. Joyce,et al.  Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response , 2015, Nature Reviews Cancer.

[11]  Laura H. Tang,et al.  Distinct functions of macrophage-derived and cancer cell-derived cathepsin Z combine to promote tumor malignancy via interactions with the extracellular matrix , 2014, Genes & development.

[12]  W. Hahn,et al.  Analysis of tumor- and stroma-supplied proteolytic networks reveals a brain metastasis-promoting role for cathepsin S , 2014, Nature Cell Biology.

[13]  M. Jäättelä,et al.  Screening and identification of small molecule inhibitors of ErbB2‐induced invasion , 2014, Molecular oncology.

[14]  S. Strittmatter,et al.  Lysosome size, motility and stress response regulated by fronto-temporal dementia modifier TMEM106B , 2014, Molecular and Cellular Neuroscience.

[15]  I. Wistuba,et al.  ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. , 2014, The Journal of clinical investigation.

[16]  J. Satoh,et al.  TMEM106B expression is reduced in Alzheimer’s disease brains , 2014, Alzheimer's Research & Therapy.

[17]  Carlos Cruchaga,et al.  TMEM106B: a strong FTLD disease modifier , 2014, Acta Neuropathologica.

[18]  C. Hoogenraad,et al.  The FTLD risk factor TMEM106B and MAP6 control dendritic trafficking of lysosomes , 2013, The EMBO journal.

[19]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[20]  J. Trojanowski,et al.  Expression of TMEM106B, the frontotemporal lobar degeneration-associated protein, in normal and diseased human brain , 2013, Acta neuropathologica communications.

[21]  M. Jäättelä,et al.  Cancer-associated lysosomal changes: friends or foes? , 2013, Oncogene.

[22]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[23]  E. Hölttä,et al.  TGF-β signaling, activated stromal fibroblasts, and cysteine cathepsins B and L drive the invasive growth of human melanoma cells. , 2012, The American journal of pathology.

[24]  G. Goodall,et al.  ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression. , 2012, The Journal of clinical investigation.

[25]  J. Trojanowski,et al.  TMEM106B, the Risk Gene for Frontotemporal Dementia, Is Regulated by the microRNA-132/212 Cluster and Affects Progranulin Pathways , 2012, The Journal of Neuroscience.

[26]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[27]  S. Hanash,et al.  Targets of the tumor suppressor miR-200 in regulation of the epithelial-mesenchymal transition in cancer. , 2011, Cancer research.

[28]  A. Ballabio,et al.  Transcriptional Activation of Lysosomal Exocytosis Promotes Cellular Clearance , 2011, Developmental cell.

[29]  Gerald C. Chu,et al.  Proinvasion metastasis drivers in early-stage melanoma are oncogenes. , 2011, Cancer cell.

[30]  Andrea Ballabio,et al.  TFEB Links Autophagy to Lysosomal Biogenesis , 2011, Science.

[31]  C. van Broeckhoven,et al.  TMEM106B a Novel Risk Factor for Frontotemporal Lobar Degeneration , 2011, Journal of molecular neuroscience : MN.

[32]  K. Sandhoff,et al.  Lysosomal degradation of membrane lipids , 2010, FEBS letters.

[33]  Alexander Pertsemlidis,et al.  Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. , 2009, Genes & development.

[34]  P. Saftig,et al.  Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function , 2009, Nature Reviews Molecular Cell Biology.

[35]  Valerio Embrione,et al.  A Gene Network Regulating Lysosomal Biogenesis and Function , 2009, Science.

[36]  J. Luzio,et al.  Delivery of endocytosed membrane proteins to the lysosome. , 2009, Biochimica et biophysica acta.

[37]  Thomas Kolter,et al.  Principles of lysosomal membrane degradation: Cellular topology and biochemistry of lysosomal lipid degradation. , 2009, Biochimica et biophysica acta.

[38]  J. Kurie,et al.  A genetic mouse model for metastatic lung cancer with gender differences in survival , 2007, Oncogene.

[39]  J. Joyce,et al.  Cysteine Cathepsins and the Cutting Edge of Cancer Invasion , 2007, Cell cycle.

[40]  B. Troen.  The Regulation of Cathepsin K Gene Expression , 2006, Annals of the New York Academy of Sciences.

[41]  M. Jäättelä,et al.  Lysosomes as targets for cancer therapy. , 2005, Cancer research.

[42]  D. Hanahan,et al.  Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. , 2004, Cancer cell.

[43]  B. Troen.  The role of cathepsin K in normal bone resorption. , 2004, Drug news & perspectives.

[44]  M. Zaidi,et al.  New insights into the regulation of cathepsin K gene expression by osteoprotegerin ligand. , 2001, Biochemical and biophysical research communications.

[45]  D. Fisher,et al.  Linking osteopetrosis and pycnodysostosis: Regulation of cathepsin K expression by the microphthalmia transcription factor family , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[46]  P. Webster,et al.  Lysosomes Behave as Ca2+-regulated Exocytic Vesicles in Fibroblasts and Epithelial Cells , 1997, The Journal of cell biology.

[47]  B. Troen,et al.  Regulation of cathepsin D gene expression in HL-60 cells by retinoic acid and calcitriol. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[48]  M. Pagano,et al.  In vitro activation of pro‐cathepsin B by three serine proteinases: leucocyte elastase, cathepsin G, and the urokinase‐type plasminogen activator , 1993, FEBS letters.

[49]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.